{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:33Z","timestamp":1792801773729,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41416-018-0369-2","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T06:02:56Z","timestamp":1547704976000},"page":"301-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis"],"prefix":"10.1038","volume":"120","author":[{"given":"Holm","family":"Eggemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Bernreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin-Andrei","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serban-Dan","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Ignatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"369_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.critrevonc.2017.03.013","volume":"113","author":"A Losurdo","year":"2017","unstructured":"Losurdo, A. et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit. Rev. Oncol. Hematol. 113, 283\u2013291 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"369_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-012-2355-3","volume":"137","author":"H Eggemann","year":"2013","unstructured":"Eggemann, H. et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res. Treat. 137, 465\u2013470 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00432-017-2539-7","volume":"144","author":"H Eggemann","year":"2017","unstructured":"Eggemann, H., Altmann, U., Costa, S. D. & Ignatov, A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J. Cancer Res. Clin. Oncol. 144, 337\u2013341 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"369_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick, J. et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360, 817\u2013824 (2002).","journal-title":"Lancet"},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","volume":"132","author":"D Grady","year":"2000","unstructured":"Grady, D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen\/progestin Replacement Study. Ann. Intern. Med. 132, 689\u2013696 (2000).","journal-title":"Ann. Intern. Med."},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","volume":"49","author":"AJ Walker","year":"2013","unstructured":"Walker, A. J., Card, T. R., West, J., Crooks, C. & Grainge, M. J. Incidence of venous thromboembolism in patients with cancer\u2014a cohort study using linked United Kingdom databases. Eur. J. Cancer 49, 1404\u20131413 (2013).","journal-title":"Eur. J. Cancer"},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1002\/cncr.24508","volume":"115","author":"RK Hernandez","year":"2009","unstructured":"Hernandez, R. K., Sorensen, H. T., Pedersen, L., Jacobsen, J. & Lash, T. L. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115, 4442\u20134449 (2009).","journal-title":"Cancer"},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell, A. et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365, 60\u201362 (2005).","journal-title":"Lancet"},{"key":"369_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/annonc\/mdr459","volume":"23","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju, N., Munsell, M. F., Hortobagyi, G. N. & Giordano, S. H. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann. Oncol. 23, 1471\u20131474 (2012).","journal-title":"Ann. Oncol."},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-#","volume":"74","author":"TF Anelli","year":"1994","unstructured":"Anelli, T. F., Anelli, A., Tran, K. N., Lebwohl, D. E. & Borgen, P. I. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74, 74\u201377 (1994).","journal-title":"Cancer"},{"key":"369_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1055\/s-0031-1273083","volume":"37","author":"D Tormene","year":"2011","unstructured":"Tormene, D., Ferri, V., Carraro, S. & Simioni, P. Gender and the risk of venous thromboembolism. Semin. Thromb. Hemost. 37, 193\u2013198 (2011).","journal-title":"Semin. Thromb. Hemost."},{"key":"369_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2011.11.025","volume":"130","author":"AA Onitilo","year":"2012","unstructured":"Onitilo, A. A. et al. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb. Res. 130, 27\u201331 (2012).","journal-title":"Thromb. Res."},{"key":"369_CR13","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","volume":"21","author":"C Duggan","year":"2003","unstructured":"Duggan, C., Marriott, K., Edwards, R. & Cuzick, J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J. Clin. Oncol. 21, 3588\u20133593 (2003).","journal-title":"J. Clin. Oncol."},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-009-0624-6","volume":"123","author":"A Ignatov","year":"2010","unstructured":"Ignatov, A., Ignatov, T., Roessner, A., Costa, S. D. & Kalinski, T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res. Treat. 123, 87\u201396 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"369_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-011-1584-1","volume":"128","author":"A Ignatov","year":"2011","unstructured":"Ignatov, A. et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res. Treat. 128, 457\u2013466 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"369_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archinte.166.7.772","volume":"166","author":"JD Curb","year":"2006","unstructured":"Curb, J. D. et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch. Intern. Med. 166, 772\u2013780 (2006).","journal-title":"Arch. Intern. Med."},{"key":"369_CR17","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith, M. R. et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 184, 1316\u20131321 (2010).","journal-title":"J. Urol."},{"issue":"Suppl 2","key":"369_CR18","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/S0049-3848(09)70015-5","volume":"123","author":"PM Sandset","year":"2009","unstructured":"Sandset, P. M., Hoibraaten, E., Eilertsen, A. L. & Dahm, A. Mechanisms of thrombosis related to hormone therapy. Thromb. Res. 123(Suppl 2), S70\u2013S73 (2009).","journal-title":"Thromb. Res."},{"key":"369_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2214\/AJR.08.2186","volume":"193","author":"RT Gupta","year":"2009","unstructured":"Gupta, R. T., Kakarla, R. K., Kirshenbaum, K. J. & Tapson, V. F. D-dimers and efficacy of clinical risk estimation algorithms: sensitivity in evaluation of acute pulmonary embolism. Am. J. Roentgenol. 193, 425\u2013430 (2009).","journal-title":"Am. J. Roentgenol."},{"key":"369_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/B:BREA.0000010701.08825.2d","volume":"83","author":"WF Anderson","year":"2004","unstructured":"Anderson, W. F., Althuis, M. D., Brinton, L. A. & Devesa, S. S. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res. Treat. 83, 77\u201386 (2004).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0369-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:05Z","timestamp":1684616645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0369-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0369-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the research meets the ethical guidelines, including adherence to the legal requirements of the study country. In accordance with the statement of the Research and Ethical Committee of the Otto-von-Guericke University, Magdeburg, Germany, written informed consent was obtained from each participant or participant\u2019s guardian before inclusion in the study. Huang C, Harada Y, Hosomi A, Masahara-Negishi Y, Seino J, Fujihira et al. Endo-beta-N-acetylglucosaminidase forms N-GlcNAc protein aggregates during ER-associated degradation in Ngly1-defective cells. Proc. Natl. Acad. Sci. USA 2015; 112, 1398-1403.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}